Thermo Fisher Scientific Inc.

WBAG:TMOF Stock Report

Market Cap: €194.4b

Thermo Fisher Scientific Valuation

Is TMOF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TMOF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TMOF (€501.1) is trading below our estimate of fair value (€808.37)

Significantly Below Fair Value: TMOF is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TMOF?

Key metric: As TMOF is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TMOF. This is calculated by dividing TMOF's market cap by their current earnings.
What is TMOF's PE Ratio?
PE Ratio33x
EarningsUS$6.14b
Market CapUS$202.33b

Price to Earnings Ratio vs Peers

How does TMOF's PE Ratio compare to its peers?

The above table shows the PE ratio for TMOF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average41.4x
DHR Danaher
42.4x13.4%US$166.7b
A Agilent Technologies
30.2x8.1%US$38.9b
LONN Lonza Group
67.1x23.4%CHF 38.5b
IQV IQVIA Holdings
25.8x13.5%US$36.3b
TMOF Thermo Fisher Scientific
33x11.5%€202.3b

Price-To-Earnings vs Peers: TMOF is good value based on its Price-To-Earnings Ratio (33x) compared to the peer average (41.4x).

Price to Earnings Ratio vs Industry

How does TMOF's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
TMOF 33.0xIndustry Avg. 37.5xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TMOF is good value based on its Price-To-Earnings Ratio (33x) compared to the European Life Sciences industry average (37.5x).

Price to Earnings Ratio vs Fair Ratio

What is TMOF's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TMOF PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate TMOF's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TMOF forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€501.10
€624.40
+24.6%
5.8%€737.01€562.32n/a29
Dec ’25€502.90
€623.86
+24.1%
5.8%€731.72€558.28n/a28
Nov ’25€514.60
€606.69
+17.9%
5.5%€709.09€554.70n/a27
Oct ’25€557.10
€589.09
+5.7%
5.9%€692.91€510.42n/a26
Sep ’25€550.90
€565.47
+2.6%
4.6%€616.93€505.17n/a25
Aug ’25€573.30
€585.60
+2.1%
4.4%€627.38€523.59n/a25
Jul ’25€508.30
€587.55
+15.6%
4.5%€632.59€516.72n/a25
Jun ’25€519.90
€576.65
+10.9%
4.5%€622.16€508.21n/a25
May ’25€535.90
€584.05
+9.0%
4.8%€633.20€517.22n/a26
Apr ’25€531.80
€551.83
+3.8%
5.5%€622.91€478.45n/a26
Mar ’25€530.40
€552.70
+4.2%
5.6%€624.74€479.86n/a25
Feb ’25€497.90
€538.24
+8.1%
5.8%€598.00€478.40n/a23
Jan ’25€482.00
€495.87
+2.9%
9.4%€579.71€394.02n/a25
Dec ’24€455.30
€496.69
+9.1%
8.8%€593.73€406.73€502.9023
Nov ’24€415.90
€505.98
+21.7%
9.2%€600.90€411.64€514.6023
Oct ’24€480.50
€588.91
+22.6%
6.3%€656.13€492.34€557.1024
Sep ’24€517.20
€580.11
+12.2%
6.2%€641.51€481.36€550.9024
Aug ’24€496.00
€571.22
+15.2%
6.2%€634.76€472.89€573.3025
Jul ’24€476.30
€576.14
+21.0%
7.2%€641.90€463.09€508.3024
Jun ’24€482.70
€584.47
+21.1%
7.2%€650.58€469.35€519.9023
May ’24€489.80
€577.80
+18.0%
7.2%€644.11€458.14€535.9022
Apr ’24€525.00
€607.25
+15.7%
7.1%€665.35€472.58€531.8022
Mar ’24€505.10
€607.25
+20.2%
7.1%€665.35€472.58€530.4022
Feb ’24€536.00
€577.55
+7.8%
8.5%€647.22€459.70€497.9019
Jan ’24€521.90
€581.30
+11.4%
8.2%€672.60€493.87€482.0022
Dec ’23€535.10
€595.86
+11.4%
8.5%€691.98€508.10€455.3020

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 21:53
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/28
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Thermo Fisher Scientific Inc. is covered by 55 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kadambari DaptardarAccountability Research Corporation
David ToungArgus Research Company
Catherine Ramsey SchulteBaird